WINTER PARK, Fla., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Alpine Income Property Trust, Inc. (NYSE: PINE) (the “Company”) today announced the sale of its former Century Theater Center in Reno, NV (the “Property”) for $5.0 million. As part of the transaction, the Company provided seller financing of $4.0 million at an annual interest rate of 8.00%, with a term of two years. The Property comprises 52,474 square feet on 1.4 acres and is almost entirely vacant following the departure of Century Theater in November ...

Core Viewpoint - Surrozen, Inc. has granted stock option awards to new employees as an inducement for their acceptance of employment, reflecting the company's commitment to attracting talent in the biotechnology sector focused on severe eye diseases [1][2][3] Group 1: Stock Option Awards - Surrozen granted a total of 45,710 stock option awards to four recently hired non-executive employees [1] - The stock options were issued under Surrozen's 2025 Equity Inducement Plan, complying with Nasdaq Listing Rule 5635(c)(4) [2] - Each stock option allows the purchase of shares at a price of $12.32 per share, which was the closing price on September 2, 2025 [2] Group 2: Vesting Schedule - The stock options will vest over a four-year period, with 25% vesting on the first anniversary of the vesting commencement date based on the employee's hire date [3] - The remaining shares will vest ratably each month thereafter, contingent on the employee's continuous service [3] Group 3: Company Overview - Surrozen is a biotechnology company focused on developing tissue-specific antibodies to modulate the Wnt pathway, particularly in the field of ophthalmology [4] - The company's proprietary technologies aim to leverage the body's biological repair mechanisms to address severe diseases [4]

Company Overview - Catheter Precision, Inc. is a U.S.-based medical device company focused on developing advanced products for the cardiac electrophysiology market [2] - The company aims to improve the treatment of cardiac arrhythmias through innovative technology and collaboration with physicians [2] Upcoming Special Meeting - A special meeting of stockholders is scheduled for October 10, 2025, with a record date of September 10, 2025 [1] - The company seeks stockholder approval to amend its Certificate of Incorporation to increase the authorized shares of common stock and to appoint WithumSmith+Brown, PC as the independent auditor for fiscal year 2026 [1] Proxy Materials - Catheter Precision plans to file proxy materials with the U.S. Securities and Exchange Commission (SEC) related to the solicitation of proxies for the special meeting [5] - Stockholders can access the Preliminary and Definitive Proxy Statement and other related documents for free on the SEC's website or the company's website [5] Participants in Solicitation - The company, its directors, and certain executive officers may be considered "participants" in the proxy solicitation for the special meeting [6] - Information regarding these participants and their interests will be included in the Proxy Statement and related materials [6]

Group 1 - Royalty Pharma will participate in the Morgan Stanley 23rd Annual Global Healthcare Conference on September 9, 2025, at 3:20 p.m. ET [1] - The webcast of the event will be available on Royalty Pharma's "Events" page and archived for at least thirty days [1] Group 2 - Royalty Pharma, founded in 1996, is the largest buyer of biopharmaceutical royalties and a key funder of innovation in the biopharmaceutical industry [2] - The company collaborates with various entities, including academic institutions, research hospitals, non-profits, and both small and mid-cap biotechnology companies, as well as leading global pharmaceutical companies [2] - Royalty Pharma's portfolio includes royalties on over 35 commercial products and 17 development-stage product candidates, featuring notable therapies such as Vertex's Trikafta and GSK's Trelegy [2]

Core Viewpoint - Sachem Capital Corp. has appointed Jeffery C. Walraven as Executive Vice President and Chief Financial Officer, effective September 1, 2025, following his role as Interim CFO since December 2024 [1][2] Company Overview - Sachem Capital Corp. is a mortgage REIT that specializes in originating, underwriting, funding, servicing, and managing a portfolio of loans secured by first mortgages on real property [4] - The company offers short-term secured, nonbanking loans to real estate investors for property acquisition, renovation, development, and improvement, with a conservative loan-to-value ratio as its primary underwriting criterion [4] Leadership Background - Jeffery C. Walraven has extensive experience in public company finance, accounting, and consulting, having previously served in various leadership roles in real estate companies [2] - His past positions include Chief Operating Officer and co-founder of Freehold Properties, Inc., and Executive Vice President and CFO of MedEquities Realty Trust, Inc. [2] - Walraven holds a Bachelor's degree in Financial Management and a Master's in Professional Accountancy, along with a CPA license [3]

Core Insights - Quanex Building Products Corporation reported a significant increase in net sales for the third quarter of 2025, reaching $495.3 million, a 76.7% increase compared to $280.3 million in the same period of 2024, primarily driven by the Tyman acquisition [1][3] - The company reaffirmed its cost synergy target, now estimating approximately $45 million in cost synergies over time, an increase from the initial projection of $30 million [1][2] - Despite challenges such as macroeconomic uncertainty and operational issues, the company remains optimistic about its prospects for profitable growth and value creation [1][2] Financial Performance - Net sales for the nine months ended July 31, 2025, totaled $1.35 billion, compared to $785.7 million for the same period in 2024 [1] - Gross margin increased to $138.0 million in Q3 2025, with a gross margin percentage of 27.9%, up from 25.3% in Q3 2024 [1] - The company reported a net loss of $276.0 million for Q3 2025, primarily due to a $302.3 million non-cash goodwill impairment [1][3] Balance Sheet and Liquidity - As of July 31, 2025, total debt stood at $733.7 million, with a leverage ratio of Net Debt to LTM Adjusted EBITDA decreasing to 2.6x [6][7] - The company's liquidity improved to $337.7 million, consisting of $66.3 million in cash and availability under its Senior Secured Revolving Credit Facility [7][8] - The company repaid over $51 million in bank debt during Q3 2025, reflecting strong cash flow [1][2] Share Repurchase Program - The Board authorized a $75 million share repurchase program, with $33.6 million remaining under the existing authorization as of July 31, 2025 [8] - During Q3 2025, the company repurchased 100,000 shares for approximately $2.1 million at an average price of $20.54 per share [8] Outlook - Quanex updated its fiscal 2025 guidance, now estimating net sales of approximately $1.82 billion and Adjusted EBITDA of approximately $235 million [9][10] - The company plans to focus on the integration of Tyman, capturing synergies, generating cash flow to pay down debt, and opportunistically repurchasing stock as macroeconomic conditions improve [2][9]

Core Insights - Coherent Corp. has launched the EDGE FL30, a 30 kW fiber laser designed for superior performance in metal cutting applications, setting a new standard for high-power, thick sheet cutting [1][4] Product Features - The EDGE FL30 features back reflection resilience, minimizing cut loss and process instability, which enhances uptime and consistency in challenging cutting scenarios [2] - Built with Coherent's active fiber technology and pump diodes, the EDGE FL30 ensures high efficiency, quality, and longevity [2] - The system utilizes FPGA-controlled EDGE FL modules, providing robust performance, redundancy, and field-replaceable options [2] Market Impact - The introduction of the EDGE FL30 is expected to improve manufacturers' throughput, reduce interruptions, and lower total cost of ownership [2] - Coherent's FSC3-Z-HP cutting head is compatible with the EDGE FL30, allowing OEMs to create next-generation cutting machines with enhanced reliability and precision [3] Industry Commitment - The EDGE FL30 will be showcased at FABTECH 2025 in Chicago, highlighting Coherent's dedication to advancing high-power fiber laser cutting technology in both the U.S. and global markets [4]

LOS ANGELES, Sept. 04, 2025 (GLOBE NEWSWIRE) -- MediaAlpha, Inc. (NYSE: MAX), the leading marketing technology platform powering real-time customer acquisition for the insurance industry, today announced that it has repurchased 3,234,894 shares of its Class A common stock at a price of $10.17 per share (a total of approximately $32.9 million) in a privately negotiated transaction with entities affiliated with Insignia Capital Group, L.P. (“Insignia”). The purchase price represents a discount of approximatel ...

Core Insights - MARA Holdings, Inc. produced 208 blocks in August 2025, maintaining the same output as the previous month despite a 6% increase in global hashrate to an average of 949 EH/s [3][6] - The company strategically increased its bitcoin holdings to 52,477 BTC, opting not to sell any BTC during the month [3][7] - MARA's energized hashrate grew by 1% month-over-month, with all containers and miners at its Texas wind farm on-site and connected, aiming for full operational status in Q4 2025 [4][6] Operational Highlights - Number of Blocks Won: 208 in August, compared to 207 in July [6] - BTC Produced: 705 BTC in August, slightly up from 703 BTC in July [6] - Average BTC Produced per Day: Remained stable at 22.7 BTC [6] - Share of Available Miner Rewards: 4.9%, unchanged from the previous month [6] - Transaction Fees as Percentage of Total: Decreased from 1.1% to 0.8% [6] - Energized Hashrate: Increased from 58.9 EH/s in July to 59.4 EH/s in August [6] Strategic Developments - MARA signed an investment agreement to acquire a 64% stake in Exaion, a subsidiary of EDF, with an option to increase ownership to 75% by 2027, expected to close in Q4 2025 [5] - The establishment of a European headquarters in Paris aims to accelerate international growth and reinforce energy partnerships [5]

HORSHAM, Pa., Sept. 04, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (Nasdaq: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, today announced the closing of its previously announced registered direct offering for the issuance and sale of 1,097,547 shares of the Company’s common stock at a per share purchase price of $2.204. Ladenburg Thalmann & Co. Inc. acted as ex ...